# US Pyrogen Testing Market

> US Pyrogen Testing Market Research Report: Size, Share, Trend Analysis By Test Type (Limulus Amebocyte Lysate Test, Recombinant Factor C Assay, In Vivo Test), By Product Type (Kit, Reagents, Instruments), By End Users (Pharmaceutical Companies, Biotechnology Companies, Clinical and Diagnostic Laboratories, Academic Research Institutions) and By Applications (Drug Testing, Medical Device Testing, Vaccine Testing) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.03%
- **2024:** $ 493.5 Million
- **2025:** $ 523.26 Million
- **2035:** $ 940 Million
- **Key Players:** Charles River Laboratories (US), Lonza Group (CH), Thermo Fisher Scientific (US), Merck KGaA (DE), WuXi AppTec (CN), Eurand (IT), GenScript (CN), Bio-Rad Laboratories (US), Hycult Biotech (NL)

**Report ID:** MRFR/LS/18158-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-pyrogen-testing-market-19705

---

## Market Summary

## **US Pyrogen Testing Market Overview**

As per MRFR analysis, the US Pyrogen Testing Market Size was estimated at 618.8 (USD Million) in 2023. The US Pyrogen Testing Market Industry is expected to grow from 652.18(USD Million) in 2024 to 1,143.71 (USD Million) by 2035. The US Pyrogen Testing Market CAGR (growth rate) is expected to be around 5.239% during the forecast period (2025 - 2035).

### **Key US Pyrogen Testing Market Trends Highlighted**

The US [Pyrogen Testing Market](../../../reports/pyrogen-testing-market-6786) is seeing significant momentum due to increasing regulatory requirements surrounding pharmaceutical and biopharmaceutical products. Regulatory bodies like the FDA are emphasizing the necessity for manufacturers to ensure the safety and efficacy of their products, heightening the need for pyrogen testing.

This shift towards stricter compliance is driving companies to adopt advanced testing methods, such as the Limulus Amebocyte Lysate (LAL) test and recombinant Factor C assays, which are becoming more popular due to their reliability and speed in detecting pyrogens. The rise in the production of sterile injectable drugs and biologics in the US is further pressing the demand for pyrogen testing to mitigate risks of contamination. There are opportunities to be explored in incorporating automation and AI into pyrogen testing processes, which can enhance speed and accuracy while reducing human error.

Additionally, as the trend of outsourcing continues, Contract Research Organizations (CROs) are seeing an increasing demand for pyrogen testing services. This allows smaller pharmaceutical firms to utilize these specialized resources without large investments in infrastructure.

In recent times, technological advancements in testing methods have provided innovative solutions to traditional challenges in pyrogen testing. This includes the development of rapid testing platforms that can deliver results in a shorter time frame, aiding manufacturers in meeting stringent production timelines and improving operational efficiency.

As the US healthcare system continues to evolve, driven by an increased focus on patient health and safety, the demand for robust pyrogen testing measures is expected to keep on increasing, hence influencing various sectors, including pharmaceuticals and medical devices significantly. Overall, the US market presents a dynamic environment for pyrogen testing, characterized by strict regulatory frameworks, growing demand for faster and more reliable testing solutions, and the potential for transformative technological advancements.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Pyrogen Testing Market Drivers**

### **Increase in Regulatory Compliance for Pharmaceutical Products**

The US Pyrogen Testing Market Industry is seeing significant growth driven by the rising demand for regulatory compliance in the pharmaceutical sector. The U.S. Food and Drug Administration (FDA) mandates rigorous safety and efficacy requirements for new pharmaceutical products, including strict pyrogen testing to ensure the absence of endotoxins.

In recent years, the FDA has enhanced its monitoring and auditing processes, resulting in an increased number of warning letters related to lapses in compliance. According to industry reports, approximately 27% of FDA inspections cited issues regarding pyrogen testing in 2022, signaling the critical importance of adhering to these regulations. This continuous push for safety and efficacy through proper pyrogen testing is expected to drive investments in testing services and technologies, thereby expanding the US Pyrogen Testing Market.

### **Growing Demand for Biologics and Biosimilars**

The increasing adoption of biologics and biosimilars is significantly contributing to the growth of the US Pyrogen Testing Market Industry. As per the FDA's reports, biologics accounted for approximately 40% of new drug approvals in recent years, and this trend is anticipated to continue. Biologics often require stringent pyrogen testing due to their complex natures and the potential for adverse reactions if pyrogens are present.

Notably, organizations like Amgen and Genentech are actively engaged in the development of biologic products, creating a corresponding increase in demand for robust pyrogen testing solutions to ensure patient safety. This rising focus on biologics and the necessity of extensive testing to meet regulatory standards are propelling growth in the US Pyrogen Testing Market.

### **Expansion of Clinical Trials in the United States**

The US Pyrogen Testing Market Industry is also experiencing growth fueled by the rising number of clinical trials being conducted within the country. According to the ClinicalTrials.gov database, there has been a steady increase in the number of registered clinical trials, with approximately 40,000 new trials started in 2022 alone.

This surge indicates a greater emphasis on developing new treatments and medications, necessitating biocompatibility evaluations, including pyrogen testing, for investigational drugs. Established organizations like Pfizer and Johnson & Johnson are at the forefront of these clinical efforts, thereby increasing demand for pyrogen testing services to ensure the safety of trial participants. The continuous expansion of clinical trials underscores the critical role of pyrogen testing in advancing medical research and therapeutics in the US.

### **Rising Incidences of Healthcare-Associated Infections**

The increasing incidences of healthcare-associated infections (HAIs) in the US are compelling healthcare entities and pharmaceutical companies to prioritize pyrogen testing. The Centers for Disease Control and Prevention (CDC) reported that nearly 1 in 31 hospital patients have at least one HAI on any given day, emphasizing the urgency of safe product manufacturing and sterilization processes.

This statistic highlights the necessity for effective pyrogen testing strategies to prevent the contamination of medical products and devices. Leading organizations such as the American Hospital Association are advocating for more stringent quality control measures, which directly influence the demand for improved pyrogen testing methodologies in the US Pyrogen Testing Market.

## **US Pyrogen Testing Market Segment Insights**

### **Pyrogen Testing Market Test Type Insights**

The US Pyrogen Testing Market is poised for considerable growth as advancements in testing methodologies enhance the industry's efficiency and reliability. Within this market, the segment concerning Test Type plays a critical role by addressing the detection of pyrogens, which are substances that can induce fever when introduced into the body.

This market is notably segmented into various testing methodologies, including the Limulus Amebocyte Lysate Test, Recombinant Factor C Assay, and In Vivo Test. The Limulus Amebocyte Lysate Test, derived from horseshoe crab blood, remains a predominant method due to its high sensitivity and specificity in detecting endotoxins, making it essential in pharmaceutical and biomedical applications.

The Recombinant Factor C Assay, an innovative alternative that utilizes synthetic biology to produce a functional substitute for the traditional Limulus test, is gaining traction for its ability to provide a more ethical and sustainable approach to pyrogen testing without compromising accuracy. Furthermore, the In Vivo Test, which involves animal models to evaluate the pyrogenic response, holds significant importance in regulatory requirements but is increasingly challenged due to ethical considerations.

As regulatory bodies focus on stricter guidelines to ensure patient safety, the demand for reliable and humane testing methods is driving innovations across these methodologies. The rising prevalence of chronic diseases and the growing need for biopharmaceuticals in the US are further stimulating the demand for effective pyrogen testing solutions. Each method has its unique advantages and applications, allowing for a comprehensive approach to pyrogen testing that caters to various industry needs. Overall, these Test Types are integral to the US Pyrogen Testing Market's landscape, reflecting the industry's commitment to maintaining product safety while embracing modern advancements.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Pyrogen Testing Market Product Type Insights**

The US Pyrogen Testing Market is characterized by its diverse Product Type segmentation, which includes Kits, Reagents, and Instruments. Kits often dominate this segment due to their comprehensive nature, allowing users to conduct pyrogen testing effectively with user-friendly components. Reagents play a crucial role as they are essential for executing various assays, facilitating the rapid detection of pyrogens in pharmaceutical and biotechnology products.

Instruments, which encompass automated systems used for testing, are increasingly gaining importance as they enhance efficiency and accuracy in pyrogen detection processes. The market trends show a rising demand for advanced testing methods in the United States, driven by stringent regulatory standards and the necessity for high-quality products in the healthcare sector. Innovations in testing technology also present opportunities for growth, as laboratories seek more efficient and reliable solutions. Overall, the focus on ensuring patient safety and compliance with regulatory requirements enhances the significance of each product type in driving the US Pyrogen Testing Market forward.

### **Pyrogen Testing Market End User Insights**

The US Pyrogen Testing Market shows a diverse range of end users, including Pharmaceutical Companies, Biotechnology Companies, Clinical and Diagnostic Laboratories, and Academic Research Institutions. Pharmaceutical Companies play a crucial role as they require stringent testing protocols to ensure product safety, as even small amounts of pyrogens can trigger adverse reactions in patients.

Biotechnology Companies also hold significant importance, focusing on innovative therapeutics that demand high-quality testing standards. Clinical and Diagnostic Laboratories contribute to the market by offering essential testing services that support various medical applications and patient care.

Furthermore, Academic Research Institutions drive advancements through rigorous research and development activities, greatly influencing industry standards and methodologies. The integration of automated and high-throughput testing methodologies across these end users is noted as a growing trend, enhancing efficiency and reliability in pyrogen testing. Each of these sectors possesses unique needs and requirements, driving targeted innovations and creating opportunities within the US Pyrogen Testing Market. This segmentation not only helps in understanding the market dynamics but also aids stakeholders in aligning their strategies to meet the demands of diverse end users effectively.

### **Pyrogen Testing Market Application Insights**

The Application segment of the US Pyrogen Testing Market encompasses critical areas such as Drug Testing, Medical Device Testing, and Vaccine Testing, each playing an essential role in ensuring the safety and efficacy of products. Drug Testing is vital for pharmaceuticals, as stringent regulations necessitate the detection of pyrogens that could compromise patient safety.

Medical Device Testing addresses the growing concerns over contamination in healthcare settings, ensuring devices used in procedures are free from harmful substances. Vaccine Testing is increasingly significant, especially in light of recent global health events, as the need for vaccines that are safe, effective, and free from pyrogenic materials has surged.

The US regulatory landscape actively supports these segments, driving advancements and fostering innovation to meet heightened standards. Recent statistics reflect a consistent rise in demand across these application areas, spurred by advancements in technology and the ongoing emphasis on patient safety. This landscape fosters opportunities for growth, as companies align their Research and Development efforts with stringent testing requirements to succeed in this dynamic market.

## **US Pyrogen Testing Market Key Players and Competitive Insights**

The US Pyrogen Testing Market has witnessed significant advancement and competition over the years, driven by the increasing demand for ensuring the safety and efficacy of pharmaceutical and medical products. Pyrogens, which are substances that can induce fever when introduced into the body, pose serious risks to patients and require rigorous testing to avoid adverse reactions.

As such, a multitude of companies have entered this sector, enhancing the landscape through innovation and the development of comprehensive testing methods including Limulus Amebocyte Lysate (LAL) tests, Monocyte Activation Tests (MAT), and recombinant Factor C assays. The competitive landscape is characterized by a mix of established players and new entrants, all seeking to tap into the growing focus on quality assurance and regulatory compliance within the healthcare industry.

Northwest Therapeutics is one of the prominent players in the US Pyrogen Testing Market, where it has established a strong foothold by focusing on high-quality testing services and technological innovation. The company benefits from a reputation built on reliability and accuracy in its testing methodologies, which include various assays to detect pyrogens in pharmaceutical products.

Leveraging advanced technology and skilled personnel, Northwest Therapeutics differentiates itself through its commitment to customer satisfaction and regulatory adherence, making it a preferred choice among pharmaceutical manufacturers and research organizations. Its robust infrastructure and strategic partnerships further enhance its market presence, enabling the company to respond effectively to the evolving demands of the pyrogen testing landscape.

Biogenuix Medsystems also holds a significant position in the US Pyrogen Testing Market, known for its comprehensive range of products and services aimed at ensuring compliance with safety standards in biopharmaceuticals. The company specializes in the development and distribution of advanced testing kits, which are crucial for detecting pyrogens in various substances.

Biogenuix Medsystems emphasizes research and development, allowing it to stay at the forefront of technology in pyrogen testing. Its market presence is reinforced by a series of strategic mergers and acquisitions that have expanded its operational capabilities and product offerings in the US. The company excels in providing tailored solutions and has built strong relationships with regulatory bodies to ensure that its products meet stringent industry requirements, thus strengthening its competitive advantage in the dynamic landscape of the pyrogen testing market.

### **Key Companies in the US Pyrogen Testing Market Include**

## **US Pyrogen Testing Market Industry Developments**

The US Pyrogen Testing Market has seen significant developments recently, primarily driven by increased regulatory scrutiny and the necessity for high-quality pharmaceuticals. Companies such as Northwest Therapeutics, Lonza, and Thermo Fisher Scientific have been ramping up their Research and Development efforts to enhance testing methods.

In August 2023, Lonza announced an expansion of their pyrogen testing capabilities at their facilities in Walkersville, Maryland, to meet rising demand from the biopharmaceutical sector. Additionally, in September 2023, WuXi AppTec launched a new suite of pyrogen testing services specifically designed for cell and gene therapies, reflecting the innovation trend.

The market also experienced notable mergers, with Merck KGaA acquiring a minority stake in a biotechnology firm focusing on pyrogen testing solutions, reported in July 2023. The continuous growth in market valuation, expected to reach over $500 million by 2025, is being fueled by increasing investments in biopharmaceuticals and stringent compliance measures.

The expansion in testing capabilities by established entities like Charles River Laboratories and Biogenuix Medsystems underscores the critical role of pyrogen testing amid ongoing advancements in medical technologies over the past few years.

## **US Pyrogen Testing Market Segmentation Insights**

### **Pyrogen Testing Market Test Type Outlook**

### **Pyrogen Testing Market Product Type Outlook**

### **Pyrogen Testing Market End User Outlook**

### **Pyrogen Testing Market Application Outlook**

## Market Drivers

### Regulatory Framework Enhancements

The evolving regulatory landscape in the United States significantly influences the pyrogen testing market. Regulatory bodies, such as the FDA, are continuously updating guidelines to ensure the safety and efficacy of medical products. These enhancements often require manufacturers to adopt more rigorous pyrogen testing protocols, thereby driving market growth. The pyrogen testing market is expected to benefit from these changes, as compliance with updated regulations is essential for product approval. For instance, the introduction of the FDA's guidance on the use of recombinant Factor C assays has prompted many companies to invest in new testing technologies. This regulatory push not only ensures patient safety but also fosters innovation within the industry, as companies seek to develop more efficient testing methods.

### Rising Awareness of Patient Safety

The heightened awareness of patient safety among healthcare professionals and consumers is a significant driver for the pyrogen testing market. As the healthcare industry increasingly focuses on quality assurance, the importance of pyrogen testing has gained prominence. The pyrogen testing market is benefiting from this trend, as healthcare providers seek to minimize the risk of pyrogen-related adverse reactions in patients. This awareness is leading to increased investments in testing services and technologies, as hospitals and manufacturers prioritize compliance with safety standards. Furthermore, educational initiatives aimed at informing stakeholders about the risks associated with pyrogens are likely to contribute to market growth. As patient safety remains a top priority, the demand for effective pyrogen testing solutions is expected to rise.

### Technological Innovations in Testing

Technological advancements play a crucial role in shaping the pyrogen testing market. Innovations such as the development of rapid testing methods and automated systems are enhancing the efficiency and accuracy of pyrogen detection. The pyrogen testing market is experiencing a shift towards more sophisticated technologies, including the use of recombinant DNA technology and high-throughput screening methods. These advancements are expected to reduce testing times significantly, which is particularly beneficial for the biopharmaceutical sector, where time-to-market is critical. As companies strive to meet the increasing demand for faster and more reliable testing solutions, investments in technology are likely to rise, further propelling market growth. The market is projected to grow at a CAGR of around 8% over the next few years, driven by these technological innovations.

### Expansion of Biopharmaceutical Sector

The expansion of the biopharmaceutical sector is a key driver for the pyrogen testing market. As the industry continues to grow, driven by advancements in biotechnology and personalized medicine, the need for effective pyrogen testing becomes increasingly critical. The pyrogen testing market is projected to see substantial growth, with estimates suggesting a market value of over $1 billion by 2027. This growth is fueled by the increasing number of biopharmaceutical products entering the market, which require stringent testing to ensure safety and efficacy. Additionally, the rise in collaborations between biopharmaceutical companies and testing laboratories is likely to enhance the availability of advanced testing solutions. As the biopharmaceutical sector expands, the demand for reliable pyrogen testing will continue to escalate.

### Increasing Demand for Sterile Products

The rising demand for sterile products in the healthcare sector is a primary driver for the pyrogen testing market. As hospitals and clinics prioritize patient safety, the need for rigorous testing of medical devices, pharmaceuticals, and biologics has intensified. The pyrogen testing market is witnessing a surge in demand, particularly in the biopharmaceutical sector, where the market is projected to reach approximately $1.5 billion by 2026. This growth is largely attributed to the increasing number of surgical procedures and the expansion of the pharmaceutical industry, which necessitates stringent quality control measures to ensure product safety. Consequently, manufacturers are investing in advanced pyrogen testing methods to comply with regulatory standards, thereby propelling the market forward.

## Future Outlook

The [Pyrogen Testing Market](https://www.marketresearchfuture.com/reports/pyrogen-testing-market-6786) is projected to grow at 6.03% CAGR from 2025 to 2035, driven by increasing regulatory requirements and advancements in testing technologies.

**New opportunities:**

- Development of rapid testing kits for on-site use Expansion of contract testing services for biopharmaceuticals Integration of AI in data analysis for enhanced testing accuracy

By 2035, the market is expected to achieve robust growth, driven by innovation and regulatory compliance.

## Segment Insights

### By Test Type: LAL Test (Largest) vs. Rabbit Pyrogen Test (Fastest-Growing)

The US pyrogen testing market is characterized by multiple test types, with the LAL test holding the largest share due to its widespread adoption for endotoxin detection in pharmaceuticals and biotechnology. This robust procedure offers high sensitivity and specificity, making it the preferred choice, particularly among manufacturers requiring compliance with strict regulatory standards. In contrast, the Rabbit Pyrogen Test, although traditionally used, is experiencing a decline in market share as alternative methods gain traction and regulatory bodies increasingly favor non-animal testing methods.

Growth trends within this segment indicate a significant shift towards alternatives like the Monocyte Activation Test and Synthetic Pyrogen Test, which are rapidly gaining popularity due to ethical considerations and technological advancements. This transition is driven by an increasing focus on reducing animal testing and the promotion of in vitro solutions that provide reliable results in pyrogen assessment. As innovation continues, the Synthetic Pyrogen Test is anticipated to emerge as a strong competitor in the market, appealing to both regulatory agencies and consumers aiming for ethical testing practices.

LAL Test (Dominant) vs. Monocyte Activation Test (Emerging)

The LAL Test remains the dominant player in the US pyrogen testing market, known for its reliability and effectiveness in detecting endotoxins in a variety of applications, including pharmaceuticals and medical devices. Its established protocols and regulatory backing lend it a competitive edge that is difficult for newer methods to overcome. Conversely, the Monocyte Activation Test is emerging as a viable alternative, offering a more humane and ethical approach by utilizing human immune cells. This test appeals to a growing segment of the market that is increasingly conscious of animal welfare and seeks compliant methods that promise accuracy and reproducibility without relying on animal subjects. As such, the Monocyte Activation Test is expected to carve a niche for itself, especially among companies prioritizing ethical testing methodologies.

### By Product Type: Reagents (Largest) vs. Kits (Fastest-Growing)

In the US pyrogen testing market, reagents account for the largest share of the product type segment, primarily due to their essential role in conducting accurate and reliable tests. Kits follow as a significant segment, enabling streamlined testing processes and contributing to increased efficiency in laboratories. Instruments, while important, have a smaller share compared to reagents and kits, reflecting their specialized application in the testing procedures.

Growth trends in the US pyrogen testing market show that the reagent segment continues to lead while kits are emerging due to a rise in demand for comprehensive testing solutions. Factors driving this growth include advancements in technology, regulatory changes favoring thorough testing protocols, and a heightened focus on patient safety, which all contribute to the increasing adoption of kits in various laboratories.

Reagents: Largest vs. Kits: Emerging

Reagents dominate the product type segment of the US pyrogen testing market, serving as the primary component necessary for conducting pyrogen tests. They are widely appreciated for their adaptability and reliability in diverse laboratory settings. Kits, on the other hand, are becoming increasingly popular as they combine all necessary components for conducting tests in a single package, facilitating ease of use. This emerging trend is supported by an increasing demand for efficiency and streamlined testing processes. Both product types are essential in meeting regulatory standards and ensuring accurate results, but reagents currently hold a more established position in the market.

### By End Use: Pharmaceuticals (Largest) vs. Biologics (Fastest-Growing)

The US pyrogen testing market is primarily driven by the pharmaceuticals segment, which holds the largest market share due to the significant need for safety and adherence to regulatory standards in drug development. Biologics also form a crucial part of this market, experiencing rapid growth from increasing investments in biopharmaceutical innovation and the consequent rise in biologic therapies.

Growth trends indicate that the pharmaceuticals segment will continue to dominate, but biologics are emerging swiftly due to technological advancements and the growing focus on personalized medicine. Research laboratories also contribute to the market by providing essential testing services. Overall, the increasing emphasis on safety and efficacy in healthcare drives the demand across these segments.

Pharmaceuticals (Dominant) vs. Biologics (Emerging)

The pharmaceuticals segment stands as the dominant force in the US pyrogen testing market, characterized by stringent regulatory requirements and heightened focus on patient safety. Companies invest heavily in pyrogen testing to comply with FDA standards, thereby ensuring that their drugs are free from pyrogens that can cause fever. On the other hand, the biologics segment is emerging rapidly, fueled by a surge in the development of biologic products and innovative therapies. This segment appeals to manufacturers due to the growing demand for advanced treatment options, prompting many firms to adopt sophisticated pyrogen testing methods to ensure the safety of these complex products. The interplay between these segments shapes the evolving landscape of the pyrogen testing market.

### By Methodology: Gel Clot Method (Largest) vs. Chromogenic Method (Fastest-Growing)

The market share distribution within the US pyrogen testing market reveals that the Gel Clot Method currently occupies the largest segment, leveraging its established effectiveness and reliability. In contrast, the Chromogenic Method is gaining traction due to its quick results and high specificity, making it increasingly popular among laboratories aiming for efficiency.

Recent trends indicate a shift toward the Chromogenic Method, driven by advancements in testing technologies and a growing emphasis on rapid testing solutions. The demand for more precise and faster results is elevating this method to the forefront, while the Gel Clot Method maintains its dominance due to its widespread acceptance and historical usage in the industry. This dynamic landscape highlights the evolving preferences of lab technicians and regulatory requirements in the pyrogen testing sector.

Testing Methodology: Gel Clot (Dominant) vs. Chromogenic (Emerging)

The Gel Clot Method is recognized as the dominant testing methodology in the US pyrogen testing market, known for its reliability and established protocols that have been in place for years. It primarily appeals to traditional testing facilities due to its proven track record. Conversely, the Chromogenic Method represents an emerging trend, appealing to laboratories focused on innovation and speed. Its ability to provide quick and accurate results positions it well within a competitive landscape, responding to the increasing demand for efficiency in testing. As regulatory bodies evolve, both methods will likely adapt to meet new standards while catering to the specific needs of users in the market.

## Competitive Benchmarking

The pyrogen testing market is characterized by a competitive landscape that is increasingly shaped by innovation, regulatory compliance, and the growing demand for biopharmaceuticals. Key players such as Charles River Laboratories (US), Thermo Fisher Scientific (US), and Lonza Group (CH) are at the forefront, leveraging their extensive portfolios and technological advancements to capture market share. Charles River Laboratories (US) focuses on enhancing its testing capabilities through strategic partnerships and acquisitions, which appear to bolster its position in the market. Meanwhile, Thermo Fisher Scientific (US) emphasizes [digital transformation](https://www.marketresearchfuture.com/reports/digital-transformation-market-8685) and automation in its testing processes, aiming to improve efficiency and accuracy in pyrogen testing. Lonza Group (CH) is also investing in expanding its service offerings, particularly in the realm of cell and gene therapies, which could potentially drive demand for pyrogen testing services. The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure is moderately fragmented, with a mix of established players and emerging companies vying for prominence. This fragmentation allows for diverse strategies, yet the collective influence of major players like Charles River Laboratories (US) and Thermo Fisher Scientific (US) tends to dominate market dynamics, shaping trends and setting benchmarks for quality and compliance. In October 2025, Charles River Laboratories (US) announced the acquisition of a leading pyrogen testing firm, which is expected to enhance its service capabilities and expand its geographical reach. This strategic move underscores the company's commitment to strengthening its market position and responding to the increasing demand for reliable testing solutions. The acquisition may also facilitate the integration of advanced technologies into their testing protocols, thereby improving overall efficiency. In September 2025, Thermo Fisher Scientific (US) launched a new line of automated pyrogen testing systems designed to streamline laboratory workflows. This innovation is likely to address the growing need for rapid and accurate testing in the biopharmaceutical sector, positioning the company as a leader in technological advancements within the market. The introduction of automation could significantly reduce turnaround times, enhancing customer satisfaction and operational efficiency. In August 2025, Lonza Group (CH) expanded its pyrogen testing services to include a new suite of assays tailored for emerging biotherapeutics. This strategic expansion reflects the company's proactive approach to meet the evolving needs of the biopharmaceutical industry. By diversifying its service offerings, Lonza Group (CH) may strengthen its competitive edge and attract a broader client base, particularly in the rapidly growing gene therapy sector. As of November 2025, the competitive trends in the pyrogen testing market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) into testing protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing service delivery. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to changing market demands.

## Recent News & Developments

The US Pyrogen Testing Market has seen significant developments recently, primarily driven by increased regulatory scrutiny and the necessity for high-quality pharmaceuticals. Companies such as Northwest Therapeutics, Lonza, and Thermo Fisher Scientific have been ramping up their Research and Development efforts to enhance testing methods.

In August 2023, Lonza announced an expansion of their pyrogen testing capabilities at their facilities in Walkersville, Maryland, to meet rising demand from the biopharmaceutical sector. Additionally, in September 2023, WuXi AppTec launched a new suite of pyrogen testing services specifically designed for cell and gene therapies, reflecting the innovation trend.

The market also experienced notable mergers, with Merck KGaA acquiring a minority stake in a biotechnology firm focusing on pyrogen testing solutions, reported in July 2023. The continuous growth in market valuation, expected to reach over $500 million by 2025, is being fueled by increasing investments in biopharmaceuticals and stringent compliance measures.

The expansion in testing capabilities by established entities like Charles River Laboratories and Biogenuix Medsystems underscores the critical role of pyrogen testing amid ongoing advancements in medical technologies over the past few years.

## Report Scope

| MARKET SIZE 2024 | 493.5(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 523.26(USD Million) |
| MARKET SIZE 2035 | 940.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.03% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Charles River Laboratories (US), Lonza Group (CH), Thermo Fisher Scientific (US), Merck KGaA (DE), WuXi AppTec (CN), Eurand (IT), GenScript (CN), Bio-Rad Laboratories (US), Hycult Biotech (NL) |
| Segments Covered | Test Type, Product Type, End Use, Methodology |
| Key Market Opportunities | Advancements in rapid testing technologies enhance efficiency in the pyrogen testing market. |
| Key Market Dynamics | Regulatory changes drive innovation and demand for advanced pyrogen testing methods in the US healthcare sector. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US pyrogen testing market in 2024?**
A: The overall market valuation was $493.5 Million in 2024.

**Q: What is the projected market valuation for the US pyrogen testing market by 2035?**
A: The projected valuation for 2035 is $940.0 Million.

**Q: What is the expected CAGR for the US pyrogen testing market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 6.03%.

**Q: Which test type had the highest valuation in the US pyrogen testing market in 2024?**
A: The LAL Test had the highest valuation at $280.0 Million in 2024.

**Q: What are the key product types in the US pyrogen testing market?**
A: Key product types include Reagents, Kits, and Instruments, with Kits valued at $380.0 Million in 2024.

**Q: Which end-use segment contributed the most to the US pyrogen testing market in 2024?**
A: The Pharmaceuticals segment contributed the most, with a valuation of $380.0 Million in 2024.

**Q: What methodologies are used in the US pyrogen testing market?**
A: Methodologies include Gel Clot, Chromogenic, and Turbidimetric methods, with the Chromogenic Method valued at $350.0 Million in 2024.

**Q: Who are the key players in the US pyrogen testing market?**
A: Key players include Charles River Laboratories, Thermo Fisher Scientific, and Merck KGaA, among others.

**Q: What is the valuation range for the Rabbit Pyrogen Test in the US pyrogen testing market?**
A: The valuation range for the Rabbit Pyrogen Test is between $120.0 Million and $220.0 Million.

**Q: How does the market for Monocyte Activation Test compare to other test types in 2024?**
A: The Monocyte Activation Test had a valuation range of $100.0 Million to $180.0 Million, indicating a lower performance compared to the LAL Test.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-pyrogen-testing-market-19705*